FARICIMAB and OFF LABEL USE

Overview

OFF LABEL USE is the #1 most commonly reported adverse reaction for FARICIMAB, manufactured by Genentech, Inc.. There are 2,275 FDA adverse event reports linking FARICIMAB to OFF LABEL USE. This represents approximately 20.4% of all 11,141 adverse event reports for this drug.

Patients taking FARICIMAB who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

OFF LABEL USE is a frequently reported adverse event for FARICIMAB, accounting for a significant proportion of all reports.

Other Side Effects of FARICIMAB

In addition to off label use, the following adverse reactions have been reported for FARICIMAB:

• NO ADVERSE EVENT — 1,900 reports
• VISUAL IMPAIRMENT — 479 reports
• DRUG INEFFECTIVE — 325 reports
• DEATH — 309 reports
• UVEITIS — 309 reports
• EYE INFLAMMATION — 306 reports
• RETINAL THICKENING — 299 reports
• ENDOPHTHALMITIS — 237 reports
• BLINDNESS — 224 reports
• VITRITIS — 218 reports

Other Drugs Associated with OFF LABEL USE

The following drugs have also been linked to off label use in FDA adverse event reports:

Does FARICIMAB cause OFF LABEL USE?

OFF LABEL USE has been reported as an adverse event in 2,275 FDA reports for FARICIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is OFF LABEL USE with FARICIMAB?

OFF LABEL USE accounts for approximately 20.4% of all adverse event reports for FARICIMAB, making it one of the most commonly reported side effect.

What should I do if I experience OFF LABEL USE while taking FARICIMAB?

If you experience off label use while taking FARICIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages